September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our ...

Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...

Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing ...

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the ...

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of ...

Results from a new study link inpatient food insecurity with longer hospitalization and greater chances of readmission.

Maternal navigation for pregnant patients who chronically miss prenatal care appointments is necessary to reduce premature ...

Clinicians, researchers, and payer experts convened in Aurora, Colorado, on August 13, 2024, for discussions on ensuring that ...

Video content above is prompted by the following: From a patient’s perspective, what are some of the advantages and disadvantages of using oral hypomethylating agents (HMAs) vs injectable HMAs? How do ...

The presidential debate showed the candidates’ differing views on women's health care, an area of medicine that currently ...

The evolving landscape of artificial intelligence (AI) use in cancer care requires evaluation of algorithms before ...

Nicolas Girard, MD, head of the Curie-Montsouris Thorax Institute, discusses patient-reported outcomes (PROs) from the phase 2 LUMINOSITY trial of telisotuzumab vedotin (Teliso-V) in non–small cell ...